Navigation Links
Bionomics Achieves US$1 Million Milestone Payment from Genmab
Date:2/19/2008

s for cancer to the clinic."

The CEO of Genmab Lisa N Drakeman, PhD commented: "We are pleased to reach the next level of development with these targets and look forward to continuing the collaboration with Bionomics."

Professor Jan G J van de Winkel, PhD, Chief Scientific Officer of Genmab added: "This milestone has been reached following extensive studies by Genmab on the Bionomics targets. The work we have undertaken has confirmed and extended the work performed by Bionomics, further supporting their potential as new targets for therapeutic antibodies."

Bionomics has the rights and is actively developing a large number of additional proprietary proteins discovered through its angiogenesis program, including BNO69. In addition Bionomics' anti-cancer drug BNC105 will soon commence a Phase 1 clinical trial at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Western Hospital cancer centres in Melbourne for the treatment of solid tumours including breast, colon and prostate cancers. BNC105 was identified using the Angene(R) platform. Bionomics' Investigational New Drug (IND) submission for BNC105 was accepted by the US Food and Drug Administration in November 2007.

About Bionomics Limited:

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' discovery and development activities are driven by its three technology platforms: Angene(R), the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore(R) is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX(R) is a set of novel technologies for the identification of drugs targeting ion channels for diseases of t
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... announces the list of stocks featured in the Analyst Blog. Every ... events impacting stocks and the financial markets. Stocks recently featured in ... Report ), Celgene (Nasdaq: CELG - Free Report ... ), Market Vectors Biotech ETF (AMEX: BBH - ... XBI - Free Report ). Today, Zacks is ...
(Date:10/31/2014)... 31, 2014 /CNW Telbec/ - Ergoresearch Ltd ... plan, for accelerated growth in terms of sales and ... reached $17,862,341. Net income amounted to $1,230,153. The EBITDA ... first time in the Company,s history. With ... the forces of its subsidiaries, merging in September 2014 ...
(Date:10/31/2014)... -- Though therapies are in their nascent phase, sales ... annual increase of 16.2% over the 2010-2020 period, reaching ... to Kalorama Information,s report, Stem Cell Therapeutics Markets ... have gained or are expected to gain approval from ... ever more complicated conditions, stem cell therapies hold the ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
... 20 Santaris Pharma announced today that,the fourth ... In the USA,several patients with cancer have now ... jointly developed by Santaris Pharma and Enzon,Pharmaceuticals. The ... Pharma­ceutical,s Investigational New Drug (IND) application,for the use ...
... Expands Overseas TBI TrialCOSTA MESA, Calif., March 19 ... that the company has received a letter from the ... forward" as a basis to resume clinical studies of ... therapeutic oxygen carrier.The letter was in response to the ...
Cached Medicine Technology:Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 2Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 3
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, 2014 (HealthDay ... is nothing new. The first kidney transplant took place ... and the first human heart transplant in 1967. By 2010, ... face. One major organ still eludes the transplant surgeon, ... U.S. scientists has its way, that dream may become reality, ...
(Date:10/31/2014)... year, people across the United States spend an estimated ... which costs $522 billion, according to new research. ... the time and wages that caregivers give up every ... daily activities. The study authors said the significant financial ... flexibility policies. "Our findings provide a new and ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... research group at the DFG Research Center for Regenerative ... Dresden (CRTD) demonstrated for the first time the in ... three dimensions from mouse embryonic stem cells. Correct spatial ... the dorsal/ventral axis was observed., This study has been ... Cell Reports " on 30.10.2014 ., For many years ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
Breaking Medicine News(10 mins):Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Facebook Websites In Thirty-Seconds 2
... clarify the disease,s connection to obesity , , TUESDAY, Dec. 30 ... their blood appear to be more likely to develop breast ... might be the link between obesity and breast cancer, say ... York City. High insulin levels have already been associated with ...
... variant had cancer as well as idiopathic pulmonary fibrosis, study ... mutation in a gene previously found to help protect the ... and some inherited cases of a lethal lung disease affecting ... in the SFTPA2 gene have been found in ...
... resident Gary Balady, MD, a cardiologist in the Division ... of medicine at the Boston University School of Medicine ... by Castle Connolly Medical Ltd. , The America,s Top ... is a trusted and authoritative resource for identifying top ...
... cruciate ligament (ACL) reconstruction can be difficult, but a review of ... edition of Sports Health: A Multidisciplinary Approach highlights how the use ... issues. , ... Rosemont, IL (Vocus) December 30, 2008 ...
... Treat Diseases (HTDS) www.htdsmedical.com (temporary site up ... it has registered with Pink Sheets for its back ... information including updating last 2 years financial statements. The ... a "Yield" rank from the current "STOP" no information ...
... with fish oil can improve health and cholesterol levels, however, new ... Approach highlights the effects of the omega fish oil on professional ... ... -- Researchers have firmly established that supplementing a diet with fish ...
Cached Medicine News:Health News:High Insulin May Boost Odds of Breast Cancer 2Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:BMC, Boston University School of Medicine cardiologist named 1 of America's Top Doctors 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 3Health News:Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players 2Health News:Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: